

【公報種別】特許法第17条の2の規定による補正の掲載

【部門区分】第3部門第2区分

【発行日】平成18年7月20日(2006.7.20)

【公表番号】特表2002-516276(P2002-516276A)

【公表日】平成14年6月4日(2002.6.4)

【出願番号】特願2000-550479(P2000-550479)

【国際特許分類】

C 07 D 235/18	(2006.01)
A 61 K 31/4184	(2006.01)
A 61 K 31/4439	(2006.01)
A 61 P 11/06	(2006.01)
A 61 P 37/08	(2006.01)
A 61 P 43/00	(2006.01)
C 07 D 401/12	(2006.01)
C 07 D 405/12	(2006.01)
C 07 D 409/12	(2006.01)
C 07 D 409/14	(2006.01)
A 61 K 45/00	(2006.01)

【F I】

C 07 D 235/18	
A 61 K 31/4184	
A 61 K 31/4439	
A 61 P 11/06	
A 61 P 37/08	
A 61 P 43/00	1 1 1
C 07 D 401/12	
C 07 D 405/12	
C 07 D 409/12	
C 07 D 409/14	
A 61 K 31/4184	
A 61 K 45:00	
A 61 K 31/4439	
A 61 K 45:00	

【手続補正書】

【提出日】平成18年5月19日(2006.5.19)

【手続補正1】

【補正対象書類名】明細書

【補正対象項目名】特許請求の範囲


【補正方法】変更

【補正の内容】

【特許請求の範囲】

【請求項1】 次の式を有する化合物であつて、

【化1】



X および Y は、H、アルキル、アルコキシ、アリール、置換されたアリール、ヒドロキシ、ハロゲン、アミノ、アルキルアミノ、ニトロ、シアノ、C F<sub>3</sub>、O C F<sub>3</sub>、C O N H<sub>2</sub>、C O N H R および N H C O R<sub>1</sub>からなる群より独立に選択され、

R は、H、C H<sub>3</sub>、C<sub>2</sub>H<sub>5</sub>、C<sub>3</sub>H<sub>7</sub>、C<sub>4</sub>H<sub>9</sub>、C H<sub>2</sub>P h、および C H<sub>2</sub>C<sub>6</sub>H<sub>4</sub>-F (p- ) からなる群より選択され、

R<sub>1</sub> および R<sub>2</sub> は、H、アリール、置換されたアリール、シクロアリール、置換されたシクロアリール、多環シクロアリール、ベンジル、置換されたベンジル、アルキル、シクロアルキル、置換されたシクロアルキル、多環シクロアルキル、縮合環脂肪族、シクロプロピル、置換されたシクロプロピル、シクロブチル、置換されたシクロブチル、シクロペンチル、置換されたシクロペンチル、シクロヘキシリル、置換されたシクロヘキシリル、シクロヘプチル、置換されたシクロヘプチル、ビシクロヘプチル、ビシクロオクチル、ビシクロノニル、置換されたビシクロアルケニル、アダマンチル、置換されたアダマンチル、および複素環からなる群より独立に選択され、R<sub>1</sub> および R<sub>2</sub> の少なくとも 1 つは芳香族基であり、R が H であるときには R<sub>1</sub> および R<sub>2</sub> の両方がフェニル基であることはない、化合物。


**【請求項 2】** R<sub>1</sub> および R<sub>2</sub> に対する置換は、アルキル、アリール、C F<sub>3</sub>、C H<sub>3</sub>、O C H<sub>3</sub>、O H、C N、C O O R および C O O H からなる群より選択される、請求項 1 に記載の化合物。

**【請求項 3】** 哺乳動物における増加した I g E レベルに関するアレルギー反応を治療または予防するための薬の調製における、請求項 1 および 2 のいずれかに記載の化合物の使用。












**【請求項 4】** 哺乳動物における喘息を治療または予防するための薬の調製における、請求項 1 および 2 のいずれかに記載の化合物の使用。

**【請求項 5】** 化合物は、


【化 2】




【化3】

















【化 4】











【化5】




【化6】




【化7】













【化 8】













【化9】













【化10】















【化 1 1】













【化 1 2】














【化 1 3】














【化14】














【化 1 5】














【化16】













【化17】














【化18】














【化 1 9】













【化20】




【化 2 1】




【化 2 2】




【化 2 3】




【化24】




(342)




(343)




(344)




(345)




(346)



(347)



(348)





(349)

からなる群より選択される、請求項 1 に記載の化合物。













【請求項 6】

【化 2 5】















(24)














【化 2 6】













【化27】








【化 2 8】



【化29】




## 【化30】



からなる群より選択される、化合物。

【請求項7】 次の式

## 【化31】



によって表わされる、化合物。

【請求項 8】 哺乳動物における増加した Ig E レベルに関するアレルギー反応を治療または予防するための医薬組成物であって、請求項 1 に記載の化合物の 1 つまたはそれ以上を含む、医薬組成物。

【請求項 9】 R<sub>1</sub> および R<sub>2</sub> に対する置換は、アルキル、アリール、C F<sub>3</sub>、C H<sub>3</sub>、O C H<sub>3</sub>、O H、C N、C O O R および C O O H からなる群より選択される、請求項 8 に記載の医薬組成物。

【請求項 10】 前記アレルギー反応に関する少なくとも 1 つの症状を減少させる活性を有する少なくとも 1 つの付加的な成分をさらに含む、請求項 8 に記載の医薬組成物。

【請求項 11】 前記付加的な成分は、短時間作用性の <sub>2</sub>-アドレナリン様アゴニスト、長時間作用性の <sub>2</sub>-アドレナリン様アゴニスト、抗ヒスタミン、ホスホジエステラーゼ阻害剤、抗コリン作用剤、コルチコステロイド、炎症媒体放出阻害剤およびロイコトリエン受容体アンタゴニストからなる群より選択される、請求項 10 に記載の医薬組成物。